JP2023548342A5 - - Google Patents

Info

Publication number
JP2023548342A5
JP2023548342A5 JP2023526539A JP2023526539A JP2023548342A5 JP 2023548342 A5 JP2023548342 A5 JP 2023548342A5 JP 2023526539 A JP2023526539 A JP 2023526539A JP 2023526539 A JP2023526539 A JP 2023526539A JP 2023548342 A5 JP2023548342 A5 JP 2023548342A5
Authority
JP
Japan
Prior art keywords
degrees
optionally substituted
alkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023526539A
Other languages
English (en)
Japanese (ja)
Other versions
JP7825618B2 (ja
JP2023548342A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/058260 external-priority patent/WO2022099011A1/en
Publication of JP2023548342A publication Critical patent/JP2023548342A/ja
Publication of JP2023548342A5 publication Critical patent/JP2023548342A5/ja
Application granted granted Critical
Publication of JP7825618B2 publication Critical patent/JP7825618B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023526539A 2020-11-06 2021-11-05 二環式１，４－ジアゼパノン及びその治療的使用 Active JP7825618B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110776P 2020-11-06 2020-11-06
US63/110,776 2020-11-06
PCT/US2021/058260 WO2022099011A1 (en) 2020-11-06 2021-11-05 Bicyclic 1,4-diazepanones and therapeutic uses thereof

Publications (3)

Publication Number Publication Date
JP2023548342A JP2023548342A (ja) 2023-11-16
JP2023548342A5 true JP2023548342A5 (https=) 2024-11-12
JP7825618B2 JP7825618B2 (ja) 2026-03-06

Family

ID=78806729

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526539A Active JP7825618B2 (ja) 2020-11-06 2021-11-05 二環式１，４－ジアゼパノン及びその治療的使用

Country Status (11)

Country Link
US (3) US11981644B2 (https=)
EP (1) EP4240724A1 (https=)
JP (1) JP7825618B2 (https=)
KR (1) KR20230122002A (https=)
CN (1) CN116635378A (https=)
AR (1) AR124008A1 (https=)
AU (1) AU2021373814A1 (https=)
CL (1) CL2023001301A1 (https=)
IL (1) IL302665A (https=)
MX (1) MX2023004745A (https=)
WO (1) WO2022099011A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11981644B2 (en) 2020-11-06 2024-05-14 Cytokinetics, Inc. Bicyclic 1,4-diazepanones and therapeutic uses thereof
WO2024040190A1 (en) * 2022-08-18 2024-02-22 Cytokinetics, Incorporated Indane and coumaran derivatives as fast skeletal muscle myosin inhibitors
CN120202194A (zh) 2022-11-16 2025-06-24 巴斯夫欧洲公司 作为杀真菌剂的取代的四氢苯并二氮杂䓬
WO2024104815A1 (en) 2022-11-16 2024-05-23 Basf Se Substituted benzodiazepines as fungicides
CN120202196A (zh) 2022-11-16 2025-06-24 巴斯夫欧洲公司 作为杀真菌剂的取代的苯并二氮杂䓬类

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
JPH09511998A (ja) 1994-04-15 1997-12-02 グラクソ、ウェルカム、インコーポレーテッド １，４ − ベンゾジアゼピン化合物を用いたコレシストキニンアゴニスト活性の誘導方法
US6410254B1 (en) 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US6743599B1 (en) 1999-05-18 2004-06-01 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7202051B1 (en) 1999-05-18 2007-04-10 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US6908921B2 (en) 2002-12-13 2005-06-21 Merck & Co., Inc. Quinoxalinone derivatives as bradykinin B1 antagonists
US20060217370A1 (en) * 2005-02-18 2006-09-28 Ethan Burstein Compounds useful for the treatment and prevention of pain and screening methods therefor
JP2009509923A (ja) 2005-08-26 2009-03-12 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼのベンゾジアゼピン及びベンゾピペラジン類似体阻害薬
PL2069352T3 (pl) 2006-08-02 2014-03-31 Cytokinetics Inc Określone cząstki chemiczne, kompozycje i sposoby
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
SI2583970T1 (sl) * 2006-08-02 2016-03-31 Cytokinetics, Inc. Določene kemijske enote, sestavki in postopki, ki obsegajo imidazopirimidine
WO2008144483A2 (en) 2007-05-18 2008-11-27 Armgo Pharma, Inc. Agents for treating disorders involving modulation of ryanodine receptors
US8455479B2 (en) 2008-01-24 2013-06-04 Panacea Biotec Limited Heterocyclic compounds
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
KR20160046693A (ko) 2012-04-02 2016-04-29 싸이토키네틱스, 인코포레이티드 횡격막 기능을 향상시키는 방법들
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CA2869675C (en) 2012-04-11 2022-06-14 Cytokinetics, Inc. Methods for improving resistance to skeletal muscle fatigue
EP2708535A1 (en) * 2012-05-11 2014-03-19 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors
US9566310B2 (en) 2012-09-10 2017-02-14 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Methods of treating muscular dystrophy
SI3137622T1 (sl) 2014-04-29 2022-05-31 Cytokinetics, Inc. Postopki za zmanjšanje upada vitalne kapacitete
JP6573618B2 (ja) 2014-09-09 2019-09-11 アステラス製薬株式会社 尿失禁予防用及び／又は治療用新規医薬組成物
SG11201806416XA (en) 2016-02-12 2018-08-30 Astellas Pharma Inc Tetrahydroisoquinoline derivatives
CA3140017A1 (en) 2019-07-19 2021-01-28 Aurore HICK Polyaromatic urea derivatives and their use in the treatment of muscle diseases
US11981644B2 (en) 2020-11-06 2024-05-14 Cytokinetics, Inc. Bicyclic 1,4-diazepanones and therapeutic uses thereof
WO2023215367A1 (en) 2022-05-04 2023-11-09 Cytokinetics, Inc. Bicyclic piperazinones and therapeutic uses thereof

Similar Documents

Publication Publication Date Title
JP2023548342A5 (https=)
ES2673160T5 (es) Moduladores selectivos del receptor de la esfingosina 1 fosfato y métodos de síntesis quiral
US9309224B2 (en) N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
JP2024543983A5 (https=)
US12012381B2 (en) Dimethyltryptamine analogues as nitric oxide delivery drugs
JP2011527334A5 (https=)
EP2210890A1 (en) Oxadiazole derivatives as S1P1 receptor agonists
JP2006501295A5 (https=)
JPWO2002062775A1 (ja) ２−アシルアミノチアゾール誘導体又はその塩
HU229935B1 (en) Dual action antibiotics
JP2007527919A5 (https=)
JP7159440B2 (ja) ジカチオン化合物及びその製造方法と使用
JPWO2023195529A5 (https=)
JP2008502614A5 (https=)
JP2013542267A5 (https=)
JP5781093B2 (ja) 新たな置換イソキノリン誘導体
JP2007532627A5 (https=)
JP2024510939A5 (https=)
BR112020016270A2 (pt) Composto atuando como antibióticos
RU2006138426A (ru) Производные тиазолопиридина, содержащие их фармацевтические композиции и способы лечения состояний, опосредованных глюкокиназой
HUP0400238A2 (hu) Pirrolidin-oxadiazol- és tiadiazolszármazékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
JP2023541040A5 (https=)
HUT58063A (en) Process for producing 5 ht under 3 antagonist heterocyclic guanidine derivatives
JP2022554330A5 (https=)
JP2022523383A5 (https=)